ESR1 and neoplasm: Supportive of this approach, we have found that in preclinical ER+ breast cancer models, vaccination against estrogen receptor alpha (ESR1) gain of function mutants results in anti-tumor responses against ESR1-mutant-expressing murine mammary cancer models [16].